Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
Takagi K, Sato N, Ishihara S, Iha H, Kobayashi N, Ito Y, Nohara T, Ohkuma S, Mitsuishi T, Ishizuka A, Shigihara S, Sone M, Nakama K, Tokuyama H, Omote T, Kikuchi A, Nakamura S, Yamamoto E, Ishikawa M, Amitani K, Takahashi N, Maruyama Y, Imura H, Shimizu W.
Takagi K, et al. Among authors: maruyama y.
J Cardiol. 2020 Nov;76(5):499-505. doi: 10.1016/j.jjcc.2020.05.012. Epub 2020 Jul 19.
J Cardiol. 2020.
PMID: 32665162
Free article.
Clinical Trial.